New combo therapy tested for Tough-to-Treat lung cancer
NCT ID NCT04396535
Summary
This study tested whether adding an immunotherapy drug called bintrafusp alfa to standard chemotherapy (docetaxel) could better control advanced non-small cell lung cancer in patients whose cancer had worsened despite previous treatment with immunotherapy and chemo. The trial aimed to see if the combination helped slow cancer growth and extend life compared to chemo alone. It was a Phase 2 study that enrolled a small number of patients but was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.